Isolated Lyssavirus Nucleic Acid and Protein Sequences


A novel strain in the rabies family of viruses, the Shimoni bat virus (SHIBV), has been discovered. Phylogenic and antigenic patterns identify SHIBV as a new species of Lyssavirus. Phylogenic reconstructions of SHIBV and monoclonal antibody typing were used to demonstrate a distinct genetic antigenic pattern. This unique genetic information may be used to create antigens or vaccines against SHIBV and provides opportunity for the development of new diagnostics, therapeutics, and prophylactic therapies for viral infection.

Potential Commercial Applications: Competitive Advantages:
  • Vaccines, therapies or diagnostics for Shimoni bat virus
  • Rabies epidemiology and surveillance
  • Lyssavirus/rabies research tool
 
  • Protects against phylogroup II lyssaviruses, unlike current commercially available rabies vaccines
  • Isolated biomaterials provide novel lyssavirus research tools


Development Stage:
  • Early-stage
  • In vitro data available


Inventors:

Ivan Kuzmin (CDC)  ➽ more inventions...

Wanda Markotter

Charles Rupprecht (CDC)  ➽ more inventions...


Intellectual Property:
PCT Application No. PCT/US11/021309
US Application No. 61/294,988

Publications:
Kuzmin IV, et al. PMID 20138934
Kuzmin IV, et al. PMID 21867415

Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:

OTT Reference No: E-179-2013-0
Updated: Sep 17, 2013